ERVW-1 and myeloid sarcoma: The MABs previously listed will be the focus of this review and other treatments completing phase II studies in MS can be found in Table 1; including some preliminary compounds in phase II such as Elezanumab, VAY736, and the HERV-W Env Antagonist GNbAC1.